TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma.

Glenn J Hanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.